Skip to main content

Table 3 Adjusted association of fibrinogen and Lp(a) categories with clinical outcomes

From: Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

Risk factor

Tertile/range

KM rates (%)

Hazard ratio

(95% CI)

p value

Lp(a) categories

Total

   

0.001

 

Lp(a)-L (< 10)

3.5

Reference

 
 

Lp(a)-M (10–29.9)

5.3

1.531

1.128–2.079

0.006

 

Lp(a)-H (≥ 30)

5.6

1.786

1.315–2.426

 < 0.001

Fibrinogen categories

Total

   

0.002

 

Fib-L(< 2.84)

4.0

Reference

 
 

Fib-M(2.85–3.42)

4.4

1.001

0.726–1.379

0.996

 

Fib-H(≥ 3.43)

6.1

1.558

1.162–2.089

0.003

Combined categories

Total

   

0.002

 

G1(Lp(a)-L + Fib-L)

3.3

Reference

 
 

G2(Lp(a)-L + Fib-M)

3.5

1.203

0.687–2.107

0.518

 

G3(Lp(a)-L + Fib-H)

4.0

1.476

0.831–2.619

0.184

 

G4(Lp(a)-M + Fib-L)

4.1

1.482

0.846–2.596

0.169

 

G5(Lp(a)-M + Fib-M)

4.9

1.511

0.866–2.636

0.146

 

G6(Lp(a)-M + Fib-H)

7.0

2.307

1.409–3.777

0.001

 

G7(Lp(a)-H + Fib-L)

4.8

1.912

1.085–3.369

0.025

 

G8(Lp(a)-H + Fib-M)

5.4

1.707

0.984–2.962

0.057

 

G9(Lp(a)-H + Fib-H)

7.2

2.656

1.628–4.333

 < 0.001

  1. Data are expressed as HR (95% CI). L low, M medium, H high. Covariates used for adjustment are age, sex, BMI, diabetes mellitus, hypertension, dyslipidemia, family history of CAD, active smoking, D-dimer, and statin treatment